Skip to content

Analysis of the Clinical Efficacy of Vitamin D in the Treatment of Sudden Deafness

Analysis of the Clinical Efficacy of Vitamin D in the Treatment of Sudden Deafness

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107606
Enrollment
Unknown
Registered
2025-08-14
Start date
2025-01-27
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sudden Sensorineural Hearing Loss

Interventions

Control group (conventional treatment group):Administer oral methylprednisolone tablets and intravenous infusion of ginkgo biloba extract injection.
experimental group (vitamin D intervention group):Administer oral methylprednisolone tablets and intravenous infusion of ginkgo biloba extract injection, along with oral vitamin D3 for treatment.

Sponsors

The First People's Hospital of Yinchuan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1. Met the diagnostic criteria for sudden sensorineural hearing loss (SSNHL) as outlined in the Guidelines for the Diagnosis and Treatment of Sudden Hearing Loss (2015) jointly formulated by the Otorhinolaryngology Head and Neck Surgery Branch of the Chinese Medical Association and the Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery [8]; 2. No history of hearing loss caused by middle/inner ear inflammation or other etiologies; 3. No prior treatment for SSNHL before enrollment; 4. Normal hearing in the contralateral (healthy) ear; 5. No family history of hereditary deafness; 6. Serum 25-hydroxyvitamin D level <75 nmol/L (30 ng/mL); 7. Patients with stable diabetes, hypertension, or coronary heart disease were included.

Exclusion criteria

Exclusion criteria: 1. Pregnant women or patients with uncontrolled systemic comorbidities;a; family history of hereditary deafness; 3. Abnormal findings in temporal bone CT or internal auditory canal MRI (e.g., structural lesions in external/middle/inner ear); 4. Affected ear with tympanic membrane perforation, fungal infection, or ear canal malformation; 5. Non-compliance with medication regimens; 6. Renal/hepatic dysfunction or multi-system organ failure; 7. Allergy to any component of vitamin D3 capsules.

Design outcomes

Primary

MeasureTime frame
Hearing improvement;Tinnitus improvement;

Countries

China

Contacts

Public ContactShenxue Liang

The First People's Hospital of Yinchuan

sxlwyt0507@163.com+86 152 0957 6277

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026